Mineralys Therapeutics, Inc. (MLYS:NASDAQ) closed at $20.55 on October 23, 2026, down 4.29% on the day. The stock trades 56.9% below its 52-week high of $47.65 and 2.1% above its 52-week low of $20.12. Over the past year, it lost 48.5%. Mineralys Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, MLYS closed higher on 108 days (43%). Its best day was November 10, 2025 (+17.04%) and its worst was June 3, 2026 (-13.14%). The stock moved 10% or more in a single session 6 times.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Find more stocks like MLYS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.